"Towards a COVID-19 vaccine to protect against SARS-CoV-2 variants and animal sarbecoviruses without updating"

To combat future SARS-CoV-2 variants and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health, we designed mosaic nanoparticles that present randomly arranged sarbecovirus spike receptor-binding domains (RBDs) to elicit antibodies against conserved epitopes. We compared immune responses elicited by mosaic-8 (SARS-CoV-2 and seven animal sarbecoviruses) and homotypic (only SARS-CoV-2 RBD) nanoparticles in mice and macaques. Mosaic-8 immunization showed equivalent neutralization of SARS-CoV-2 variants, including Omicrons, and protected from SARS-CoV-2 and SARS-CoV challenges, whereas homotypic SARS-CoV-2 immunization protected only from SARS-CoV-2 challenge. Epitope mapping of antisera demonstrated increased targeting of conserved epitopes after mosaic-8 compared with homotypic nanoparticle immunization. Together, these results suggest that mosaic-8 RBD nanoparticles could protect against SARS-CoV-2 variants and future sarbecovirus spillovers.

Event Information

- Virtual Lecture
- Once you register, you will be e-mailed a Zoom Link

You can also call in using:

- Phone: +1 669 900 6833
- Meeting ID: 910 6153 8225

Pamela Bjorkman, PhD
- David Baltimore Professor of Biology and Biological Engineering; Merkin Institute Professor
- Caltech

JAN 17, 2023
11:00am - 12:00pm PST

Scan to register for the Grand Rounds lecture

Questions/Comments: Rina Lee-Cha, rlee@mednet.ucla.edu